Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients-Reference-Cited by-同舟云学术

Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients

Published:2012-11-02 Issue:11 Volume:7 Page:e48372
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Schiavon Gaia,Ruggiero Alessandro,Schöffski Patrick,van der Holt Bronno,Bekers Dave J.,Eechoute Karel,Vandecaveye Vincent,Krestin Gabriel P.,Verweij Jaap,Sleijfer Stefan,Mathijssen Ron H. J.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference45 articles.

1. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);EA Eisenhauer;Eur J Cancer,2009

2. New guidelines to evaluate the response to treatment in solid tumors;P Therasse;J Natl Cancer Inst,2000

3. RECIST revisited: a review of validation studies on tumour assessment;P Therasse;Eur J Cancer,2006

4. The evolution of imaging in cancer: current state and future challenges;LJ Higgins;Semin Oncol,2011

5. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria;H Choi;J Clin Oncol,2007

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monitoring neoadjuvant treatment-induced surgical benefit in GIST patients using CT-based radiological criteria;Surgery Open Science;2024-08

2. Levels of circulating tumor DNA correlate with tumor volume in gastro‐intestinal stromal tumors: an exploratory long‐term follow‐up study;Molecular Oncology;2024-05-24

3. A Monte Carlo simulation-based decision support system for radiation oncologists in the treatment of glioblastoma multiforme;Radiation and Environmental Biophysics;2024-04-25

4. Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma;Clinical Lung Cancer;2024-01

5. Elimusertib has anti-tumor activity in preclinical patient-derived pediatric solid tumor models;Molecular Cancer Therapeutics;2023-12-30